L Mazzolai, G Teixido-Tura, S Lanzi, V Boc… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations, off-label use of medication should be limited to situations where it is in the patient's interest …
JM Guirguis-Blake, CV Evans, LA Perdue, SI Bean… - Jama, 2022 - jamanetwork.com
Importance Low-dose aspirin is used for primary cardiovascular disease prevention and may have benefits for colorectal cancer prevention. Objective To review the benefits and …
F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of …
Члены Комитета экспертов подтвердили отсутствие финансовой поддержки/конфликта интересов. В случае сообщения о наличии конфликта интересов, член (ы) Комитета …
Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and …
Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and …
JM Gaziano, C Brotons, R Coppolecchia, C Cricelli… - The Lancet, 2018 - thelancet.com
Background The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in …
Importance The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk. Objective To assess the …